RNA analysis market seen reaching $19.04 billion by 2030

The global RNA analysis and transcriptomics market is projected to nearly double from $8.74 billion in 2025 to $19.04 billion by 2030, driven by demand in precision medicine, drug discovery and clinical diagnostics. North America leads now, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - RNA analysis and transcriptomics are becoming core tools for studying gene expression, disease biology and treatment development. - The market’s growth points to expanding use across drug discovery, diagnostics and personalized medicine. - Rising chronic disease rates are increasing demand for technologies that can detect disease-linked changes in RNA activity earlier and more precisely.

What happened: - The Business Research Company said the RNA analysis/transcriptomics market reached $8.74 billion in 2025. - The market is projected to rise to $10.22 billion in 2026. - The market is forecast to reach $19.04 billion by 2030. - The company put the market’s 2026-2030 CAGR at 16.8%. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Transcriptomics, or RNA analysis, studies the transcriptome, the full set of RNA molecules expressed in a cell or tissue under specific conditions. - High-throughput methods are central to the field. - The market’s recent growth has been fueled by genomic research, RNA sequencing adoption, life sciences investment, advanced laboratory instruments and more academic research activity. - Future growth is expected to come from precision medicine demand, transcriptomics use in drug discovery, clinical diagnostics based on gene expression, bioinformatics investment and personalized therapeutic approaches. - Major trends include wider use of next-generation sequencing platforms, high-throughput transcriptomic profiling, sophisticated bioinformatics tools, single-cell RNA analysis and a stronger focus on reproducibility and data accuracy. - The company’s market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - A free sample report is available here. - The full report is available here.

Between the lines: - The forecast suggests RNA analysis is moving from a research-heavy niche toward broader commercial and clinical use. - Growth in chronic disease diagnoses, including pre-diabetes, supports demand for molecular tools that can refine screening and treatment selection. - The region mix suggests the market is already mature in North America, while Asia-Pacific has more room to scale.

What's next: - Transcriptomics adoption is likely to keep expanding as more labs, drugmakers and diagnostics developers build gene-expression data into workflows. - Bioinformatics and data-quality tools should gain importance as datasets become larger and more complex. - The company expects single-cell analysis and next-generation sequencing to remain major growth areas through 2030.

The bottom line: - RNA analysis/transcriptomics is on a steep growth path, with clinical and precision-medicine uses likely to drive the biggest gains.